CN105832724A - 吲哚醇在制备抗抑郁症药物中的用途 - Google Patents
吲哚醇在制备抗抑郁症药物中的用途 Download PDFInfo
- Publication number
- CN105832724A CN105832724A CN201610158225.9A CN201610158225A CN105832724A CN 105832724 A CN105832724 A CN 105832724A CN 201610158225 A CN201610158225 A CN 201610158225A CN 105832724 A CN105832724 A CN 105832724A
- Authority
- CN
- China
- Prior art keywords
- formula
- depression
- medicine
- indanol
- compound shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title abstract description 6
- XAWPKHNOFIWWNZ-UHFFFAOYSA-N 1h-indol-6-ol Chemical compound OC1=CC=C2C=CNC2=C1 XAWPKHNOFIWWNZ-UHFFFAOYSA-N 0.000 title abstract description 5
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 41
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 16
- YIAPLDFPUUJILH-UHFFFAOYSA-N indan-1-ol Chemical compound C1=CC=C2C(O)CCC2=C1 YIAPLDFPUUJILH-UHFFFAOYSA-N 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000007924 injection Substances 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 11
- 229940005513 antidepressants Drugs 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000000857 drug effect Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 26
- 238000012360 testing method Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 13
- 229960004801 imipramine Drugs 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 238000012048 forced swim test Methods 0.000 description 8
- 230000009182 swimming Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000004904 shortening Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000581650 Ivesia Species 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 229960002102 imipramine hydrochloride Drugs 0.000 description 4
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002964 excitative effect Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000003889 chemical engineering Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- KHWHYHFZHBCYDB-UHFFFAOYSA-N 6,7-dihydrocyclopenta[c]pyridin-5-one Chemical compound N1=CC=C2C(=O)CCC2=C1 KHWHYHFZHBCYDB-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510671062 | 2015-10-16 | ||
CN201510671062X | 2015-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105832724A true CN105832724A (zh) | 2016-08-10 |
CN105832724B CN105832724B (zh) | 2018-07-03 |
Family
ID=56394169
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610158225.9A Active CN105832724B (zh) | 2015-10-16 | 2016-03-18 | 吲哚醇在制备抗抑郁症药物中的用途 |
CN201610158023.4A Pending CN105770357A (zh) | 2015-10-16 | 2016-03-18 | 蒜氨酸在制备抗抑郁症药物中的用途 |
CN201610494641.6A Active CN106038522B (zh) | 2015-10-16 | 2016-06-28 | 大黄酸在制备抗抑郁症药物中的用途 |
CN201610695266.1A Active CN106176748B (zh) | 2015-10-16 | 2016-08-19 | 去甲异波尔定在制备抗抑郁症药物中的用途 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610158023.4A Pending CN105770357A (zh) | 2015-10-16 | 2016-03-18 | 蒜氨酸在制备抗抑郁症药物中的用途 |
CN201610494641.6A Active CN106038522B (zh) | 2015-10-16 | 2016-06-28 | 大黄酸在制备抗抑郁症药物中的用途 |
CN201610695266.1A Active CN106176748B (zh) | 2015-10-16 | 2016-08-19 | 去甲异波尔定在制备抗抑郁症药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN105832724B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110251559A (zh) * | 2019-07-29 | 2019-09-20 | 西南交通大学 | 一种乌药块茎提取物在制备抗抑郁药物中的应用 |
CN112168968A (zh) * | 2020-09-25 | 2021-01-05 | 中山大学附属第八医院(深圳福田) | Fto抑制剂在制备防治乳腺癌产品中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2127808A (en) * | 1982-10-01 | 1984-04-18 | Tanabe Seiyaku Co | A process for preparing a hydroxyindole |
US5380739A (en) * | 1992-05-13 | 1995-01-10 | Syntex (U.S.A.) Inc. | Substituted indole derivatives |
CN1711082A (zh) * | 2002-11-15 | 2005-12-21 | 埃尔比昂股份公司 | 新的羟基吲哚类化合物、其作为磷酸二酯酶4抑制剂的应用、以及其制备方法 |
CN101327289A (zh) * | 2008-07-31 | 2008-12-24 | 倪健 | 黄花菜及黄花菜总黄酮的新用途 |
CN103816095A (zh) * | 2007-07-09 | 2014-05-28 | 巴斯夫美容护理法国公司 | 高级糖化终产物的去糖化 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440747A (zh) * | 2003-03-31 | 2003-09-10 | 中国人民解放军肾脏病研究所 | 大黄酸或大黄酸盐在制备治疗肥胖症药物中的应用 |
CN1269527C (zh) * | 2003-06-03 | 2006-08-16 | 陈坚 | 复方蒜氨酸粉针剂 |
CN100453080C (zh) * | 2005-09-28 | 2009-01-21 | 上海中医药大学 | 乌药生物碱及其制备方法与在制药中的应用 |
CN101375850B (zh) * | 2008-10-07 | 2010-08-25 | 中国药科大学 | 去甲异波尔定在制备治疗自身免疫性疾病药物中的应用 |
CN102060809B (zh) * | 2009-05-01 | 2015-05-20 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种大黄酸衍生物及其制备和用途 |
-
2016
- 2016-03-18 CN CN201610158225.9A patent/CN105832724B/zh active Active
- 2016-03-18 CN CN201610158023.4A patent/CN105770357A/zh active Pending
- 2016-06-28 CN CN201610494641.6A patent/CN106038522B/zh active Active
- 2016-08-19 CN CN201610695266.1A patent/CN106176748B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2127808A (en) * | 1982-10-01 | 1984-04-18 | Tanabe Seiyaku Co | A process for preparing a hydroxyindole |
US5380739A (en) * | 1992-05-13 | 1995-01-10 | Syntex (U.S.A.) Inc. | Substituted indole derivatives |
CN1711082A (zh) * | 2002-11-15 | 2005-12-21 | 埃尔比昂股份公司 | 新的羟基吲哚类化合物、其作为磷酸二酯酶4抑制剂的应用、以及其制备方法 |
CN103816095A (zh) * | 2007-07-09 | 2014-05-28 | 巴斯夫美容护理法国公司 | 高级糖化终产物的去糖化 |
CN101327289A (zh) * | 2008-07-31 | 2008-12-24 | 倪健 | 黄花菜及黄花菜总黄酮的新用途 |
Also Published As
Publication number | Publication date |
---|---|
CN106176748B (zh) | 2019-01-18 |
CN106038522B (zh) | 2019-08-16 |
CN106176748A (zh) | 2016-12-07 |
CN105770357A (zh) | 2016-07-20 |
CN106038522A (zh) | 2016-10-26 |
CN105832724B (zh) | 2018-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103432184B (zh) | 牛蒡子提取物在制药或食品中的应用 | |
CN105832724A (zh) | 吲哚醇在制备抗抑郁症药物中的用途 | |
CN103356620A (zh) | 双苄基异喹啉类化合物或其在药学上可接受的盐治疗和改善抑郁症状的新用途 | |
CN107149601A (zh) | 青蒿素类化合物在制备治疗神经病理性疼痛和/或并发症的药物中的应用 | |
CN1638772A (zh) | 抗病毒化合物 | |
CN106038534B (zh) | 冬凌草甲素在制备抗抑郁症药物中的用途 | |
CA3069462A1 (en) | Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity | |
CN105012356B (zh) | 灵芝酸a在抗抑郁症中的用途 | |
CN103705774A (zh) | 一种具有治疗抑郁症作用的复方组合物及其制备方法与应用 | |
CN106265713B (zh) | 虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物 | |
CN103860578A (zh) | 香菇多糖作为抗抑郁症药物的用途 | |
CN105919991B (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
CN104000815B (zh) | 一种含有4-羟基-2-氧代-1-吡咯烷乙酰胺的药物组合物及其应用 | |
CN1939328A (zh) | 葛根素注射用制剂 | |
CN101732248B (zh) | 一种酒石酸美托洛尔注射液及其制备方法 | |
CN110003157A (zh) | 一种具有抗焦虑作用的新型黄酮类化合物及其应用 | |
CN110833553A (zh) | 吡唑并嘧啶衍生物在治疗Arthus反应的用途 | |
CN102462696B (zh) | 乌骨鸡黑色素提取物在制备防治抑郁症的药物中的用途 | |
CN112870206B (zh) | 甘露糖在制备预防脑型疟疾药物中的应用 | |
CN110711198B (zh) | D-甘露糖在制备抗抑郁药物中的应用 | |
CN105878258A (zh) | 类叶升麻苷在制备抗抑郁药物中的用途 | |
RU2395278C1 (ru) | Способ получения комплексного препарата для профилактики и лечения патологий обмена веществ и нарушений функций иммунной системы животных | |
CN104027349A (zh) | 泊洛沙姆188在制备预防和/或治疗帕金森症的药物中的应用 | |
Gholami et al. | A Case report of hemodynamic instability, cardiac arrest, and acute severe dyspnea subsequent to inhalation of crystal methamphetamine | |
CN105213398B (zh) | 一种治疗糖尿病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220602 Address after: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee after: Luo Yongqiang Address before: Room b273, innovation building, No. 29, shengshengyuan Road, Science Park, Changping District, Beijing 102206 Patentee before: BEIJING GRAGEN BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231206 Address after: Floor 3, Building 402, Zone 1, Tiantong Dongyuan, Dongxiaokou Town, Changping District, Beijing, 102218 Patentee after: Beijing Yasheng Bohou Biotechnology Development Center Address before: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee before: Luo Yongqiang |